Regulatory press release9/30/2024, 12:30 PMBulletin from the extraordinary general meeting of Calliditas Therapeutics AB (publ)
Regulatory press release9/16/2024, 1:30 PMDelisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
Regulatory press release9/3/2024, 10:15 AMCalliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
Regulatory press release9/3/2024, 10:00 AMNotice of extraordinary meeting of Calliditas Therapeutics AB (publ)
Regulatory press release8/13/2024, 5:00 AMCalliditas Therapeutics: Calliditas Interim Report January to June 2024
Press release8/5/2024, 5:00 AMCalliditas Therapeutics: Invitation to the presentation of Calliditas's interim report January - June 2024
Press release7/26/2024, 3:00 PMCalliditas Therapeutics: Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
Regulatory press release7/26/2024, 6:00 AMCalliditas Therapeutics: Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
Press release7/4/2024, 6:30 AMCalliditas Therapeutics: Launch of Phase 3 clinical trial with Nefecon in Japan
Regulatory press release6/17/2024, 3:30 PMBulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
Regulatory press release5/30/2024, 6:00 PMCalliditas Therapeutics: Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy
Press release5/28/2024, 12:00 PMCalliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress
Regulatory press release5/28/2024, 6:30 AMStatement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation